Abstract:Obesity is a leading preventable cause of death worldwide with increasing prevalence in adults and children. It is one of the most serious public health problems of the twenty-first century. Visfatin, known as pre-B-cell colony-enhancing factor (PBEF) and nicotinamide phosphoribosyltransferase (Nampt), is regarded as a novel adipokine and may have a function as a direct proinflammatory mediator of obesity-related vascular disorders with a potential role in plaque destabilisation. Visfatin/PBEF/Nampt is preferentially expressed by visceral adipose tissue compared with subcutaneous fat. AMP-activated protein kinase (AMPK) is a key molecular player in energy homoeostasis at both cellular and whole-body levels. AMPK has been shown to have a role in the physiological regulation of fatty acid and glucose metabolism, and in the regulation of appetite and body weight. Therefore, AMPK is considered a major player in the development of obesity. The model of diet-induced obesity (DIO) in rats has many features in common with human obesity and can serve as a useful model to study the pathogenesis and treatment of obesity. In Wistar rats, half the rats become hyperphagic and develop DIO, whereas the rest are diet-resistant (DR) when the rats are fed with a high fat (44% fat) diet. The present study investigated the relationship between visfatin and AMPK in DIO and DIO-restricted rats. Male Sprague–Dawley rats (n 110) at 3 weeks of age were randomly assigned into groups. Ten rats were fed rat chow during the study as the control and 100 rats were fed both rat chow plus high fat diet (HFD, 5.58 kcal/g (23.34672 kJ/g) with 66.5% as fat) ad libitum for 14 weeks. At the end of this period, forty-four rats developed DIO which was assessed by the Lee obesity index. The Lee obesity index was calculated by dividing the cube root of body weight (g) by body length (cm) · 1000. The DIO rat’s Lee obesity index was more than the average Lee obesity index plus 2 SD of the chow-fed control rats. At week 15, ten chow-fed control rats were kept on the rat chow, eleven DIO rats were kept on the rat chow plus HFD ad libitum and the other eleven DIO rats that were designated as DIO-restricted, were restricted on the intake of the rat chow plus HFD for 5 weeks. Other rats were used in other studies (data not presented). Plasma visfatin concentration was significantly lower in both DIOrestricted and chow-fed control rats than DIO rats and was 69 and 70% of DIO rats, respectively. DIO-restricted rats had significantly lower visfatin expression in the visceral adipose tissue than DIO rats, however, they had significantly higher visfatin expression than chow-fed control rats (Fig. 1). Moreover, the activity of AMPK in the visceral adipose tissue tended to be higher in both DIO-restricted and chow-fed control rats than DIO rats (Fig. 1). These results indicate that visfatin and AMPK may play important roles in the development of obesity. The lowered visfatin expression and elevated AMPK activity in visceral adipose tissue in DIO-restricted rats may stimulate fatty acid oxidation, and we hypothesise that inactive visfatin and activate AMPK may be of therapeutic targets in obesity.

Activin E-ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice

Hepatic Activin E mediates liver-adipose inter-organ communication, suppressing adipose lipolysis in response to elevated serum fatty acids

Activin E Controls Energy Homeostasis in Both Brown and White Adipose Tissues as a Hepatokine

Activin E enhances insulin sensitivity and thermogenesis by activating brown/beige adipocytes

Activin E upregulates uncoupling protein 1 and fibroblast growth factor 21 in brown adipocytes

Activin Receptor ALK4 Promotes Adipose Tissue Hyperplasia by Suppressing Differentiation of Adipocyte Precursors

Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity

Enhanced C/EBPβ function promotes hypertrophic versus hyperplastic fat tissue growth and prevents steatosis in response to high-fat diet feeding

Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction–associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease

Human ACVR1C missense variants that correlate with altered body fat distribution produce metabolic alterations of graded severity in knock-in mutant mice

Chromatin Accessibility Analysis Identifies the Transcription Factor ETV5 As a Suppressor of Adipose Tissue Macrophage Activation in Obesity

Acetylation of Cavin-1 Promotes Lipolysis in White Adipose Tissue.

Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143

Adipose-tissue Treg Cells Restrain Differentiation of Stromal Adipocyte Precursors to Promote Insulin Sensitivity and Metabolic Homeostasis

Angiotensin(1-7) attenuates visceral adipose tissue expansion and lipogenesis by suppression of endoplasmic reticulum stress via Mas receptor

Implication of activin E in glucose metabolism: transcriptional regulation of the inhibin/activin betaE subunit gene in the liver

Overexpression of Adiponectin Receptor 1 Inhibits Brown and Beige Adipose Tissue Activity in Mice

Loss of adipose ATF3 promotes adipose tissue lipolysis and the development of MASH

Visfatin As a Novel Adipokine in Relation to AMP-activated Protein Kinase in Obesity and Weight Loss

The Role of Acetyl-CoA Synthetase Short Chain Family Member-1 on Adipocyte Thermogenic Capacity

311-OR: Role of Pcpe2 in Adipose Tissue Remodeling and Expansion